Resources

Current study in Lancet showed that patients reduced their A1c levels by 1.55%.

Only GLP-1 receptor agonist for use with mealtime or basal insulin for adults with type 2.

Even though amputation is not a major effect, it is still important to let patients know about it and how to prevent it with proper foot care.

As problems for Tandem continue, and with Johnson & Johnson abandoning the insulin pump market, it’s beginning to dawn on some people that we soon could live in a world with just two insulin pump companies – Medtronic and Insulet.

Therapy said superior to a basal/bolus insulin regimen at lowering HbA1c with less hypoglycemia and weight gain.

GLP-1 receptor agonists vs DPP-4 inhibitors: In head-to-head trials of dipeptidyl peptidase 4 (DPP-4) inhibitors vs glucagon-like peptide 1 (GLP-1) receptor agonists, GLP-1 receptor agonists showed more favorable outcomes in all of the following areas except which one of the following? A. Greater glycemic control B. Greater tolerability C. Greater weight loss D. Greater improvement in beta-cell function E. Greater reduction in postprandial triglycerides Follow the link to see if you got it right!

When was the last time you rode a bike? a) Days b) Weeks c) Months d) Years e) Decades ago f) Never! Follow the link to see how you compare to your colleagues!

Woman, 63 years of age, history of ovarian cancer, prediabetes, hyperlipidemia, has been trying to lose weight for years but was unable to do so. She is very family-, friend-, colleague-oriented. Every holiday she thought she had to make or bring and eat whatever special holiday food was associated with the holiday. She couldn’t let anyone down by not bringing, or by not eating what other people brought. We met weekly for the past three years. Every week there was some excuse about how or why she “cheated” or if there was a week she didn’t think she “cheated,” then she was afraid she would.

In this Exclusive Interview transcript, Dr. Richard Bergenstal discusses the first approval of a hybrid closed-loop system and the future of diabetes treatment, including a possible cure for type 1 diabetes.

In this Exclusive Interview, Dr. Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed about the technology in the artificial pancreas, the new Abbott Libre CGMS, and the possible diabetes cure.